Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.)
• Content Notes:
  Purpose -- COVID-19 vaccines -- Groups recommended for vaccination -- Primary series -- Booster dose -- Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised -- Interchangeability of COVID-19 vaccine products -- Coadministration of COVID-19 vaccines with other vaccines -- COVID-19 vaccination and SARS-CoV-2 infection -- Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks -- Considerations involving pregnancy, lactation, and fertility -- Vaccination of children and adolescents -- Patient counseling -- Considerations for mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna -- Considerations for Janssen COVID-19 Vaccine -- Contraindications and precautions -- Reporting of vaccine adverse events -- Laboratory testing -- Appendix A. Vaccine administration errors and deviations -- Appendix B. Guidance for People who are Moderately or Severely Immunocompromised and Vaccinated with Janssen COVID-19 Vaccine -- Appendix C: Triage of people with a history of allergies or allergic reactions -- Appendix D: Ingredients included in COVID-19 vaccines -- Appendix E. People who received COVID-19 vaccine outside the United States -- Appendix F. People.
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Vaccines
• Document Type:
  Webpage
• Place as Subject:
  United States
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:e77e0c622a993deeae9eace333eeaa0ab18a88e2ae6b6f8ba463216244003792
• Download URL:
  https://stacks.cdc.gov/view/cdc/114489/cdc_114489_DS1.pdf
• File Type:
  [PDF - 6.23 MB ]